Stockholders' Equity (Tables)
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2024 |
Dec. 31, 2023 |
| Stockholders' Equity |
|
|
| Summary of Stock Option Activities |
The following table summarizes stock option activities for the nine months ended September 30, 2024:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average |
|
|
|
|
|
|
|
Remaining |
|
|
|
|
Weighted Average |
|
Contractual Life (in |
|
|
Stock Options |
|
Exercise Price |
|
years) |
Outstanding at December 31, 2023 |
|
1,521 |
|
$ |
4,297.50 |
|
3.31 |
Outstanding at September 30, 2024 |
|
1,521 |
|
$ |
4,297.50 |
|
2.56 |
Options vested and exercisable at September 30, 2024 |
|
951 |
|
$ |
4,297.50 |
|
2.56 |
|
The following table summarizes stock option activities for the years ended December 31, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average |
|
|
|
|
|
|
|
Remaining |
|
|
|
|
Weighted Average |
|
Contractual Life (in |
|
|
Stock Options |
|
Exercise Price |
|
years) |
Outstanding at December 31, 2021 |
|
1,521 |
|
$ |
4,297.50 |
|
5.31 |
Outstanding at December 31, 2022 |
|
1,521 |
|
$ |
4,297.50 |
|
4.31 |
Outstanding at December 31, 2023 |
|
1,521 |
|
$ |
4,297.50 |
|
3.31 |
Options vested and exercisable at December 31, 2023 |
|
951 |
|
$ |
4,297.50 |
|
3.31 |
|
| Schedule of Stock-Based Compensation Expense |
The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended September 30, |
|
For the nine months ended September 30, |
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
General and administrative |
|
$ |
52 |
|
$ |
119 |
|
$ |
150 |
|
$ |
381 |
Research and development |
|
|
(10) |
|
|
(19) |
|
|
(650) |
|
|
(1) |
Total stock-based compensation expense |
|
$ |
42 |
|
$ |
100 |
|
$ |
(500) |
|
$ |
380 |
|
The following table summarizes stock-based compensation expense for the years ended December 31, 2023 and 2022 (in thousands).
|
|
|
|
|
|
|
|
|
For the year ended December 31, |
|
|
2023 |
|
2022 |
General and administrative |
|
$ |
436 |
|
$ |
700 |
Research and development |
|
|
132 |
|
|
1,583 |
Total stock-based compensation expense |
|
$ |
568 |
|
$ |
2,283 |
|
| Summary of Warrant Activities |
A summary of warrant activities for the nine months ended September 30, 2024, is presented below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average |
|
|
|
|
|
|
|
Remaining |
|
|
|
|
Weighted Average |
|
Contractual Life (in |
|
|
Warrants |
|
Exercise Price |
|
years) |
Outstanding as of December 31, 2023 |
|
89,618 |
|
$ |
67.16 |
|
5.34 |
Exercised |
|
(409,816) |
|
|
0.01 |
|
— |
Granted |
|
1,539,314 |
|
|
9.75 |
|
2.50 |
Outstanding as of September 30, 2024 |
|
1,219,116 |
|
$ |
14.39 |
|
2.73 |
|
A summary of warrant activities for years ended December 31, 2023 and 2022, is presented below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average |
|
|
|
|
|
|
|
Remaining |
|
|
|
|
Weighted Average |
|
Contractual Life (in |
|
|
Warrants |
|
Exercise Price |
|
years) |
Outstanding as of December 31, 2021 |
|
4,393 |
|
$ |
6,036.53 |
|
0.73 |
Expired |
|
(4,003) |
|
|
6,375.00 |
|
— |
Granted |
|
997 |
|
|
601.58 |
|
9.18 |
Outstanding as of December 31, 2022 |
|
1,387 |
|
$ |
1,152.94 |
|
8.29 |
Exercised |
|
(1) |
|
|
0.08 |
|
— |
Granted |
|
88,232 |
|
|
50.09 |
|
5.29 |
Outstanding as of December 31, 2023 |
|
89,618 |
|
$ |
67.16 |
|
5.34 |
|
| Restricted stock award |
|
|
| Stockholders' Equity |
|
|
| Schedules of Restricted Stock and Restricted Stock Unit Activity |
The following table summarizes restricted stock award activities for the nine months ended September 30, 2024:
|
|
|
|
|
|
|
|
|
|
Weighted Average |
|
|
|
|
Grant Date Fair |
|
|
Number of Shares |
|
Value |
Nonvested at December 31, 2023 |
|
1,285 |
|
$ |
577.50 |
Vested |
|
(90) |
|
|
2,722.50 |
Nonvested at September 30, 2024 |
|
1,195 |
|
$ |
415.95 |
|
Certain employees and directors have been awarded restricted stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted stock award activities for the years ended December 31, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
Weighted Average |
|
|
|
|
Grant Date Fair |
|
|
Number of Shares |
|
Value |
Nonvested at December 31, 2021 |
|
369 |
|
$ |
3,034.04 |
Granted |
|
475 |
|
|
523.50 |
Vested |
|
(169) |
|
|
3,671.23 |
Nonvested at December 31, 2022 |
|
675 |
|
$ |
1,107.83 |
Granted |
|
720 |
|
|
345.00 |
Vested |
|
(110) |
|
|
2,310.00 |
Nonvested at December 31, 2023 |
|
1,285 |
|
$ |
577.50 |
|
| Restricted stock units |
|
|
| Stockholders' Equity |
|
|
| Schedules of Restricted Stock and Restricted Stock Unit Activity |
Certain employees and consultants have been awarded restricted stock units with time-based vesting. The following table summarizes restricted stock units’ activities for the nine months ended September 30, 2024:
|
|
|
|
|
|
|
|
|
|
Weighted Average |
|
|
|
|
Grant Date Fair |
|
|
Number of Units |
|
Value |
Nonvested at December 31, 2023 |
|
1,911 |
|
$ |
948.25 |
Forfeited |
|
(1,313) |
|
|
912.15 |
Vested |
|
(365) |
|
|
1,205.20 |
Nonvested at September 30, 2024 |
|
233 |
|
$ |
749.14 |
|
The following table summarizes restricted stock units’ activities for the year ended December 31, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
Weighted Average |
|
|
|
|
Grant Date Fair |
|
|
Number of Units |
|
Value |
Nonvested at December 31, 2021 |
|
3,108 |
|
$ |
2,311.00 |
Granted |
|
1,943 |
|
|
565.63 |
Forfeited |
|
(689) |
|
|
1,906.78 |
Vested |
|
(1,059) |
|
|
2,239.62 |
Nonvested at December 31, 2022 |
|
3,303 |
|
$ |
1,391.48 |
Granted |
|
577 |
|
|
256.51 |
Forfeited |
|
(1,027) |
|
|
1,374.25 |
Vested |
|
(942) |
|
|
1,614.25 |
Nonvested at December 31, 2023 |
|
1,911 |
|
$ |
948.25 |
|